Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780243 | 0.76 | TSHR (0.50) | CA2CA12CA1CA9CA14 | |
| SCHEMBL6633059 | 0.74 | MAPT (0.38) | TSHRALDH1A1PTGS2MAPTHPGD | |
| SCHEMBL16267153 | 0.74 | ALDH1A1 (0.44) | SRD5A2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL4957915 | 0.74 | TSHR (0.48) | CA2CA12CA1CA9CA14 | |
| SCHEMBL865712 | 0.74 | TSHR (0.44) | CA2CA1SRD5A2TSHRALDH1A1 | |
| SCHEMBL4030667 | 0.74 | TPMT (0.44) | CA2CA1TSHRTP53KDM4E | |
| SCHEMBL27417951 | 0.74 | CA1 (0.50) | CA2CA12CA1CA9CA14 | |
| SCHEMBL8418372 | 0.73 | TSHR (0.35) | CA2CA12CA1CA9CA14 | |
| SCHEMBL4023309 | 0.71 | MAPT (0.42) | TSHRALDH1A1PTGS2LMNAMAPT | |
| SCHEMBL11773691 | 0.70 | CA12 (0.55) | CA2CA12CA1CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| CN-113105411-A | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-110330465-A | Hydrazone amide derivatives and its application in preparation prevention and treatment alopecia agent | 深圳市三启药物开发有限公司 | 2019-10-15 | — | — | CN | claimed |
| CN-110229118-A | Hydrazone amide derivatives and its preparing the application in osteosporosis resistant medicament | 深圳市三启药物开发有限公司 | 2019-09-13 | — | — | CN | claimed |
| CN-110003123-A | For treating the PGI2 receptor modulators of prostacyclin (PGI2) receptor associate disorder | 艾尼纳制药公司 | 2019-07-12 | — | — | CN | claimed |
| US-10000443-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2018-06-19 | — | — | US | claimed |
| CN-105837411-A | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | 俄亥俄州立大学 | 2016-08-10 | — | — | CN | claimed |
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2016-05-19 | — | — | US | claimed |
| CN-104262267-A | Modulators Of The Prostacyclin (pgi2) Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARM INC | 2015-01-07 | — | — | CN | claimed |
| EP-2549863-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | Ohio University (US) | 2013-01-30 | — | — | EP | claimed |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2012-05-17 | — | — | US | claimed |
| WO-2011119866-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2011-09-29 | — | — | WO | claimed |
| CN-102036659-A | PGI2 receptor modulators for the treatment of prostacyclin receptor-related disorders | ARENA PHARM INC | 2011-04-27 | — | — | CN | claimed |
| JP-2002544260-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1178964-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000069826-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | claimed |
| CN-110003123-B | Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders | 艾尼纳制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113105411-B | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-113105411-A | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-110330465-B | Hydrazone amide derivative and application thereof in preparation of alopecia prevention and treatment medicines | 深圳市三启药物开发有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-110229118-B | Hydrazone amide derivative and application thereof in preparation of anti-osteoporosis drugs | 深圳市三启药物开发有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-110330465-A | Hydrazone amide derivatives and its application in preparation prevention and treatment alopecia agent | 深圳市三启药物开发有限公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-110229118-A | Hydrazone amide derivatives and its preparing the application in osteosporosis resistant medicament | 深圳市三启药物开发有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-110003123-A | For treating the PGI2 receptor modulators of prostacyclin (PGI2) receptor associate disorder | 艾尼纳制药公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-104262267-B9 | PGI2 receptor modulators for the treatment of prostacyclin (PGI2) receptor-related disorders | 艾尼纳制药公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-104262267-B | For treating the PGI2 receptor modulators of prostacyclin (PGI2) receptor associate disorder | 艾尼纳制药公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-104262267-A | Modulators Of The Prostacyclin (pgi2) Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARM INC | 2015-01-07 | — | — | CN | disclosed |
| CN-102036659-B | PGI2 receptor modulators for the treatment of prostacyclin receptor-related disorders | ARENA PHARM INC | 2014-09-17 | — | — | CN | disclosed |
| CN-103483226-A | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARM INC | 2014-01-01 | — | — | CN | disclosed |
| CN-102036659-A | PGI2 receptor modulators for the treatment of prostacyclin receptor-related disorders | ARENA PHARM INC | 2011-04-27 | — | — | CN | disclosed |
| US-7291440-B2 | Containing an acidic copolymer containing units from an unsaturated monomer containing a carboxyphenylurea group, e.g., 1-(m-isopropenyl-alpha,alpha-dimethylbenzyl)-3-(carboxyphenyl)urea; useful as lithographic printing plate precursors | EASTMAN KODAK COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2006124280-A1 | BAKEABLE MULTI-LAYER IMAGEABLE ELEMENT | EASTMAN KODAK COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060257764-A1 | Containing an acidic copolymer containing units from an unsaturated monomer containing a carboxyphenylurea group, e.g., 1-(m-isopropenyl-alpha,alpha-dimethylbenzyl)-3-(carboxyphenyl)urea; useful as lithographic printing plate precursors | EASTMAN KODAK COMPANY | 2006-11-16 | — | — | US | disclosed |
| CN-1276035-C | Water-color ink | MITSUI CHEMICALS INC (JP) | 2006-09-20 | — | — | CN | disclosed |
| CN-1558934-A | Water-color ink | 三井化学株式会社 | 2004-12-29 | — | — | CN | disclosed |
| US-20040231558-A1 | Has a clear hue, high light fastness and high moisture resistance | MITSUI CHEMICALS, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1441013-A1 | WATERCOLOR INK | Mitsui Chemicals, Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| EP-1441013-A1 | WATERCOLOR INK | Mitsui Chemicals, Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | CA2 827/4885CA12 3001/4885CA1 2307/4885 |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | CA2 827/4885CA12 3001/4885CA1 2307/4885 |
| US-10000443-B2 | Compositions and methods for glucose transport inhibition | SLC2A1, SLC2A4, SLC2A3 | CA2 827/4885CA12 3001/4885CA1 2307/4885 |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SOST, HDAC5, PTH1R | CA2 1239/4885CA12 2488/4885CA1 916/4885 |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | FH, HDGF, HRH4 | CA2 342/4885CA12 415/4885CA1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.